Physician + Biotech Builder with Tome Biosciences' Rahul Kakkar, M.D.

Business Of Biotech

We love to hear from our listeners. Send us a message.

Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kakkar’s worldview is shaped by his work as a physician—work he continues at Brigham and Women’s Hospital even as he builds Tome Biosciences, where he serves as President & CEO. Tome, which is developing programmable genomic integration technology, is the latest of Dr. Kakkar’s entrepreneurial efforts—he previously led Pandion Therapeutics to a $1.85B acquisition by Merck and Cordivia to a $2.1B acquisition by Novo Nordisk. On this episode of the Business of Biotech, Dr. Kakkar shares why he took on the brainchild of two MIT scientists under his wing, the nascent inflection point for gene editing therapy, how his work as a physician informs his biotech leadership, biopharma’s bad rap, and a whole lot more.

Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.

Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: https://www.linkedin.com/in/matthewpillar/

Chapters

1. Physician-Turned-Biotech CEO's Unique Journey (00:00:00)

2. Navigating Career in Medicine and Biotech (00:10:10)

3. Navigating Shifts in Biopharmaceutical Ventures (00:24:19)

4. Navigating Challenges and Struggles in Leadership (00:35:01)

5. DNA Editing Technology (00:41:00)

6. Biotech's Role in Changing Pharma Perception (00:53:58)